Showing posts with label urologie. Show all posts
Showing posts with label urologie. Show all posts

Thursday 12 November 2020

Radiofrequency treatment alters cancer cell phenotype

We are at the doorstep of an exciting era in which the due importance of Radiofrequency treatment for cancer (and possibly many other ailments) is being finally and gradually revealed.

Multiple studies are being conducted into this exciting field and plausible explanations of pathways are being suggested. Field in which these selective non-thermal effects have been shown include, and are not limited to treatment of Non-Small Cell Lung Cell Carcinoma, Glioblastoma, Bladder Cancer and Pancreatic Cancer.

Synergo incorporates a 915MHz generator, responsible for delivering microwave (the high end of the RF frequencies) in the treatment of bladder cancer. This RF is regulated in real-time by the operator (up to 36W).

One of the questions that is often raised is what effect the RF has on the cancer cells.

In vitro studies have demonstrated that tumor-specific frequencies identified in patients with various forms of cancer are capable of blocking the growth of tumor cells in a tissue- and tumor-specific fashion. Current experimental evidence suggests that tumor-specific modulation frequencies regulate the expression of genes involved in migration and invasion and disrupt the mitotic spindle.

2 independent studies present explanations to these effects and how RF operates.

An article published in 2015 by Ware et al. demonstrates that RF radiation creates micropores selectively on cancer cells and disconnects the adhesion between cancer cells. The writers conclude that there are clear phenotypical differences observed between cancerous and normal cells in both their untreated states and in their response to RF therapy. They also reported, for the first time, a transfer of microsized particles through tunneling nanotubes, which were produced by cancer cells in response to RF therapy. They provided evidence that various sub-populations of cancer cells heterogeneously respond to RF treatment.

Another article published by Curley et al. in 2014 compared how RF and hyperthermia (HT) treatments change the proliferation rate, oxygen consumption and autophagy in malignant and nonmalignant cells and their results were clear.

Their conclusion: “The results obtained in the current study, along with our previous reports, indicate the ability of RF treatment to provide a tumor-specific cytotoxic effect by inhibiting the proliferation and mitochondrial activity of tumor cells and the stimulation of autophagy. These effects exceed the hyperthermic property of the RF field. All of this assures further investigation of the biological effects of RF treatment to stimulate the development of novel, non-invasive approaches for cancer treatment using electromagnetic fields.”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199010/

https://pubmed.ncbi.nlm.nih.gov/26165830/

Monday 27 July 2020

Radiofrequency impairs viability of bladder cancer cells and has an additive effect when combined with chemotherapeutics in vitro

Presented by I.S.G. Brummelhuis et al. ESUR, Porto

A study comparing the effects of two techniques combined with chemotherapy on cell viability of bladder cancer cells in vitro.

 

MMC and epirubicin showed the greatest impact on the cell viability of all cell lines. RF-induced HT inhibited cell viability of T24, J82 and RT4 cancer cell lines. In combination with MMC and epirubicin this effect was additive. The majority of the effects of RF-induced HT were not attributable to the effect of HT, implying that the effect of RF adds independently to the effects of HT and chemotherapy. The cell viability of benign hbSMC was not affected by RF. 


European Urology Supplements 18(8):e3152-e3153 · October 2019
 

Saturday 25 August 2018

"Knowledge of drug diffusion mechanisms into the tissue and cellular cytoplasm following bladder
instillation is a key to understand the safety profile and clinical activity of chemotherapy."

Intravesical Chemotherapy and Chemohypherthermia in Non-Muscle-Invasive Bladder
Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics
Campodonico F, Di Stasi S, Lev GM, Terrone C, Bongiovanni L, Mattioli F, Pagliarulo V and Introini C
Current Drug Metabolism, 2017

https://doi.org/10.2174/1389200218666170427092421

Despite the widely adopted international guidelines’ recommendations, and recent clinical trials of device-assisted chemotherapy instillations showing markedly enhanced recurrence-free survival compared even to the standard of care, clinicians and pharmacologists are not familiar with the in-depth physical aspects, pharmacokinetics and systemic absorption of chemotherapeutic drugs following their intravesical
administration. This paper gives a comprehensive review covering various aspects of different treatments with intravesical drugs.
Device-assisted therapies have set a goal to potentiate the drug’s effect and efficacy. The Radiofrequency-Induced Thermochemotherapeutic Effect (RITE) and the Electromotive-Drug Administration (EMDA) are the two most relevant modalities used to increase the activity of intravesical chemotherapy.

This new published study examined whether RF-CHT (using Synergo system) results in higher MMC drug tissue concentrations as compared to cold MMC instillation.

Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue,
F. Johannes P. van Valenberg, Antoine G. van der Heijden, Rianne J. M. Lammers, Johannes Falke, Tom J. H. Arends, Egbert Oosterwijk & J. Alfred Witjes
International Journal of Hyperthermia


Patients received either (1) cold drug instillation (Mitomycin) or (2) RF-CHT (Synergo) before a planned transurethral resection operation. After instillation, three biopsy tests were taken of both normal and tumour tissue. The results showed that the median drug concentration in tumour tissue was higher in the RF-CHT (Synergo) group (median 665.00ng/g vs. 63.75ng/g, U¼51.0, p¼0.018). Moreover, in both techniques the MMC concentration was lower in normal tissue compared to tumour tissue. They concluded that Intravesical RF-CHT results in higher tumour MMC concentrations vs. cold MMC instillation which contributes to its superior efficacy.



virtual London (EAU 2017)
Enjoyed meeting all urology specialists at the last EAU conference!

Sunday 25 May 2014

Erlangen Urology meeting 2014


The last urology meeting in Erlangen was well organized and the Synergo® RITE was well located! Few words in German for those who came to share experience and also just to express their interest. Below is Ms. Reich and her booth neighbour dressed in traditional Bavarian costume.

Es ist uns eine Freude, unsere neuen erfahrenen klinischen Fachleute im Team von Synergo® willkommen zu heißen, die uns bei der Ausdehnung unserer Aktivitäten mit urologischen Kliniken in Deutschland und Österreich helfen werden. Unser Ziel besteht darin, urologischen Kliniken eine Verbesserung von Ausbildung, Service und Unterstützung zu bieten. Wir erweitern unsere Aktivitäten mit der Synergo® Technologie, die überall auf der Welt zunehmend routinemäßig für die Behandlung von Patienten mit Blasenkrebs im mittleren Stadium oder mit hohem Risiko eingesetzt wird.

Frau Naama Reich, unsere medizinische Kontaktperson,  
40. Gemeinsamen Tagung der Bayerischen Urologenvereinigung sowie der Österreichischen Gesellschaft für Urologie und Andrologie zu treffen. Erlangen (Germany) 2014

Synergo® RITE (durch Radiofrequenz induzierter Thermo-Chemotherapie-Effekt) gegen nicht muskel-invasiven Blasenkrebs.